TurmericNCT07196514
Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy Older Adults
A study testing Raw turmeric shots in people with Turmeric and Placebo, run by Nottingham Trent University at 1 site in United Kingdom.
Trial summary
Curcumin (a bioactive compound found in turmeric) has demonstrated anti-inflammatory and antioxidant properties, and there is evidence to suggest that it may produce improvements in quality of life and markers of health in humans with various conditions. Read more about this study
- Who is it for?
- Ages 40 to 95 yearsHealthy volunteers can take part
- What is being tested?
- Raw turmeric shots
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Oct 2025to 21 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 95 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Body Mass Index between 18.5-39.9.
Who cannot join
- History of, or currently diagnosed with, a cardiovascular disease.
- Diagnosed with diabetes.
- Diagnosed with a liver, lung, or kidney disease.
- Diagnosed with osteoporosis.
- Diagnosed with dementia.
- Diagnosed with cancer.
Show all 10Show fewer
- Use of medications/supplements/herbal remedies with human evidence of a significant interaction with turmeric.
- Allergy to turmeric, lemon, black pepper, watermelon, water, pineapple, magnesium or vitamin C.
- Pregnant, attempting to become pregnant, or breastfeeding.
- Regular (once per week or more) use of turmeric shots / supplements within the last 3 months.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Nottingham Trent University, Clifton campus
Nottingham, NG11 8NS
About this study
Official title: Exploring the Effects of an 8-week Turmeric Supplementation on Aspects of Physiology and Wellbeing in Healthy Older Adults
Curcumin (a bioactive compound found in turmeric) has demonstrated anti-inflammatory and antioxidant properties, and there is evidence to suggest that it may produce improvements in quality of life and markers of health in humans with various conditions. To date, the research has often focussed on the effects of curcumin in human participants with a particular condition. However, turmeric contains hundreds of other bioactive compounds (including other curcuminoids and essential oils) and may be able to benefit a wide range of older adults. Therefore, the aim of this study is to investigate the effects of twice daily consumption of a turmeric beverage for 8-weeks on the physiology and wellbeing of older adults (versus placebo).
- Being tested
- Raw turmeric shots, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Raw turmeric shotsDietary supplement
This group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks.
PlaceboOther
This group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | This group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks. Receives: Other: Placebo |
| Turmeric | Experimental | This group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks. Receives: Dietary Supplement: Raw turmeric shots |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma/serum Brain-derived neurotrophic factor
Measured using ELISA. We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum total cholesterol
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Chalder Fatigue Scale (CFS)
This questionnaire measures participants' severity of physical and mental fatigue. This will be scored "Likert style" from 0-33. Higher scores indicate greater levels of fatigue.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Secondary outcomes (29)
Plasma/serum creatinine
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Depression Anxiety Stress Scales - 21 items (DASS-21)
Participants choose from a range of questions designed to measure the severity of a range of symptoms common to both depression and anxiety. Scoring is based on a likert scale where higher scores relate to increased severity of depression, anxiety and stress.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
McGill Pain Questionnaire
This questionnaire is used to evaluate a person experiencing significant pain. It can be used to monitor pain over time. Someone experiencing no pain would score 0 while the maximum score for pain would be 78.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
36-Item Short Form Survey (SF-36)
This survey consists of generic questions covering eight health domains: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. To score the survey, firstly, responses to items relate to scores between 0-100. Secondly, using a table, items in the same scale are averaged together to create the eight domains.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum ALT
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum AST
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum LDL cholesterol
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum HDL cholesterol
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum ALP
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Serum GGT
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum LDH
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum creatine kinase
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum C-reactive protein
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum triglycerides
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum glucose
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Blood pressure
Systolic and diastolic blood pressure will be determined using an automatic upper arm blood pressure monitor. We will analyse raw and percentage change values.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Body mass
Determined by weighing participants.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a tool used for assessing quality and disturbances over a one-month period. The sum of scores for the following 7 components, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime function, are used to calculate a global PSQI score with scores greater than 5 indicating poor sleep quality.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
N-back task for working memory (cognitive function)
This particular N-back tast comprises of only the 2-Back memory load. The total stimulus set is 15. Participants respond using the space bar when they see a stimulus that is presented two steps previously. There are three blocks consisting of 25 trials. Each stimulus will be presented for 500 ms and get 3 seconds to respond unless the participant responds earlier in which case the next trial will begin. Errors, correct responses, misses and reaction time, will be used as indices of performance. Commission errors or 'false alarms' occur when participants respond to non-targets.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Corsi forward block test for visuospatial working memory (cognitive function)
Participants are shown squares/blocks that light up one-by-one in a random order starting in a sequence length of two blocks. Participants then click with the mouse the blocks in exactly the same order as shown before. One extra square is added to each successfully completed sequence. If the participant fails to click the correct sequence they get one more chance with a different pattern and same sequence length. If they get it wrong again, the test ends and their score is shown (the corsi block span).
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Corsi backward block test for visuospatial working memory (cognitive function)
This test is the reverse of the forward version. Participants are shown squares/blocks that light up one-by-one in a random order starting in a sequence length of two blocks. Participants then click with the mouse the blocks in the reverse order as shown before. One extra square is added to each successfully completed sequence. If the participant fails to click the correct sequence, they get one more chance with a different pattern and same sequence length. If they get it wrong again, the test ends and their score in shown (the corsi block span).
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Sit-to-Stand Test
The objective of this test is to complete as many sit-to-stand repetitions as possible in 30 seconds. Participants will be instructed to sit in the middle of a chair placed against the wall with a seat height of 43 cm. Participants start with their feet flat on the floor, arms crossed at the wrists and held against the chest. On the signal, participants will rise to a full stand and return back to a fully seated position (counting as one full repetition). Before the test, participants will be allowed to practice 1-2 times to familiarise themselves with the movement
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Hand Grip Strength Test
Participants will start by holding a hand grip dynamometer with their arm at a right angle and the elbow should be by the side of the body. The grip length will be noted and kept the same post intervention laboratory visit. Once the participant has a comfortable grip on the dynamometer they will squeeze the dynamometer with maximum isometric effort and maintain it for at least 5 seconds. No other body movement is allowed. The value shown on the dynamometer in kilograms will be recorded. Participants will alternate hands attempting the test three times with each hand.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
2-minute Step Test
The objective of this test is to complete as many steps (with the knee reaching the marking) in 2-minutes as possible. To mark the line for the knee to cross, the distance between participant's anterior iliac crest and their patella will be measured and the midpoint will be found. A piece of tape will be placed on the stadiometer corresponding height of the midpoint between the patella and the iliac crest. The final score will be the number of times the right knee reached the tape height.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Waist circumference
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Waist to hip ratio
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Physical activity levels
A wrist monitor will allow for classifications of physical activity intensities (sedentary behaviour, light intensity physical activity, moderate intensity physical activity, moderate-vigorous intensity physical activity and vigorous intensity physical activity) and durations of time spent in these classifications.
Measured: Two one week periods: One week prior to intervention (baseline) and last week of intervention (week 8)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Participants that have osteoarthritis will complete this questionnaire. The highest possible score is 96, which indicates the maximum pain, stiffness and difficulty with physical function.
Measured: Two timepoints: 1) baseline 2) after 8 week intervention
Pain medication usage
Pain medication usage over the prior 8 weeks will be assessed using a modified version of the Quantitative Analgesic Questionnaire.
Measured: Two timepoints: 1) Baseline 2) after 8 week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start6 Oct 2025
- Primary completion21 Jul 2026
- Study completion21 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TurmericStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nottingham Trent University
- Sponsor type
- University, hospital or other
- Collaborators
- Innate-Essence Limited
- Responsible party
- Principal investigator, John Hough, Nottingham Trent University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07196514
- Sponsor's protocol ID
- 2268061
- Status last verified
- Oct 2026
- First submitted
- 19 Sep 2025
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Effects of an 8-week Turmeric Supplementation on Aspects of Physiology and Wellbeing in Healthy Older Adults
- ClinicalTrials.gov ID
- NCT07196514
- Acronym / sponsor ID
- 2268061
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Nottingham Trent UniversityUniversity, hospital or other
- Collaborators
- Innate-Essence Limited
- Study start
- 6 Oct 2025 (actual)
- Primary completion
- 21 Jul 2026 (actual)
- Study completion
- 21 Jul 2026 (actual)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Curcumin (a bioactive compound found in turmeric) has demonstrated anti-inflammatory and antioxidant properties, and there is evidence to suggest that it may produce improvements in quality of life and markers of health in humans with various conditions. To date, the research has often focussed on the effects of curcumin in human participants with a particular condition. However, turmeric contains hundreds of other bioactive compounds (including other curcuminoids and essential oils) and may be able to benefit a wide range of older adults. Therefore, the aim of this study is to investigate the effects of twice daily consumption of a turmeric beverage for 8-weeks on the physiology and wellbeing of older adults (versus placebo).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: PlaceboThis group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks. |
| Turmeric | Experimental | Dietary Supplement: Raw turmeric shotsThis group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks. |
Who may qualify
- Ages
- 40 to 95 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Body Mass Index between 18.5-39.9.
Key exclusion criteria (10 listed)
- History of, or currently diagnosed with, a cardiovascular disease.
- Diagnosed with diabetes.
- Diagnosed with a liver, lung, or kidney disease.
- Diagnosed with osteoporosis.
- Diagnosed with dementia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Raw turmeric shotsThis group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks. | Dietary supplement | Turmeric |
| PlaceboThis group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks. | Other | Placebo |
Primary outcome
Plasma/serum Brain-derived neurotrophic factor
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Measured using ELISA. We will analyse raw and percentage change values.
Plasma/serum total cholesterol
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Measured using pentra C400 clinical chemistry analyser, We will analyse raw and percentage change values.
Chalder Fatigue Scale (CFS)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
This questionnaire measures participants' severity of physical and mental fatigue. This will be scored "Likert style" from 0-33. Higher scores indicate greater levels of fatigue.
29 secondary outcomes
Plasma/serum creatinine
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Depression Anxiety Stress Scales - 21 items (DASS-21)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
McGill Pain Questionnaire
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
36-Item Short Form Survey (SF-36)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum ALT
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum AST
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum LDL cholesterol
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum HDL cholesterol
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum ALP
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Serum GGT
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum LDH
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum creatine kinase
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum C-reactive protein
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum triglycerides
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Plasma/serum glucose
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Blood pressure
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Body mass
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
N-back task for working memory (cognitive function)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Corsi forward block test for visuospatial working memory (cognitive function)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Corsi backward block test for visuospatial working memory (cognitive function)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Sit-to-Stand Test
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Hand Grip Strength Test
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
2-minute Step Test
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Waist circumference
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Waist to hip ratio
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Physical activity levels
Time frame: Two one week periods: One week prior to intervention (baseline) and last week of intervention (week 8)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: Two timepoints: 1) baseline 2) after 8 week intervention
Pain medication usage
Time frame: Two timepoints: 1) Baseline 2) after 8 week intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Turmeric
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Recruiting
Effect of Curcumin Topical Spray on Wound Healing After Tooth Extraction
Wound Healing, Alveolitis of Jaw
Recruiting
Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis
Pulmonary Tuberculosis
Active, not recruitingObservational study
Effect of Moringa Oleifera, Zingiber Officinale, and Curcuma Xanthorrhiza Extracts for Nausea and Vomiting in First-Trimester Pregnancy
Nausea and Vomiting in Pregnancy
Not yet recruiting
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Raw turmeric shots in people with Turmeric and Placebo, run by Nottingham Trent University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma/serum Brain-derived neurotrophic factor (time frame: Two timepoints: 1) baseline 2) after 8 week intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.